Lawrence Friedhoff, MD, PhD

Dr. Friedhoff has worked in the pharmaceutical industry for nearly 40 years. He served as Chief of Research & Development at Roivant Sciences, Inc. since November 2016. He previously served as Roivant’s Senior Vice President, Research & Development from the company’s inception through November 2016. From 2003 to 2014, Dr. Friedhoff served as Chief Executive Officer and President of Pharmaceutical Special Projects Group, LLC, a drug development consulting company to international pharmaceutical companies. From 1998 to 2003, Dr. Friedhoff served as Executive Vice President, Research and Development of Andrx Corporation, leading its Branded Drug Development efforts. From 1988 to 1998, Dr. Friedhoff worked for subsidiaries of Eisai, Co. Ltd., ultimately serving as Executive Vice President, Research and Development of Eisai, Inc., where he led the drug development team for Aricept, a branded drug used to treat Alzheimer’s disease. Prior to Eisai, Dr. Friedhoff worked for ER Squibb, Inc., and he currently serves as a director of Senex Biotechnology, Inc. Dr. Friedhoff received his M.D. from the New York University School of Medicine and his Ph.D. in Chemistry from Columbia University Graduate School.